Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
Chelsea C. Pinnix(The University of Texas MD Anderson Cancer Center), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Maria Alma Rodriguez(The University of Texas MD Anderson Cancer Center), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Hun Ju Lee(The University of Texas MD Anderson Cancer Center), Swaminathan P. Iyer(The University of Texas MD Anderson Cancer Center), Luis Fayad(The University of Texas MD Anderson Cancer Center), Misha Hawkins(The University of Texas MD Anderson Cancer Center), Jillian R. Gunther, Sherry Adkins(The University of Texas MD Anderson Cancer Center), Paolo Strati(The University of Texas MD Anderson Cancer Center), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Penny Fang, Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Michael Wang(St. Joseph Health System), Bouthaina S. Dabaja, Ranjit Nair(NewYork–Presbyterian Brooklyn Methodist Hospital), Raphaël Steiner(The University of Texas MD Anderson Cancer Center)
Cited by 224
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
|JAMA Oncology|2019|829
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782